Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance (Q48217300)

9 February 2018

title

Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance (English)

1 reference

9 February 2018

author

Christian Funck-Brentano

object named as

C Funck-Brentano

6

0 references

author name string

E Funck-Brentano

1

1 reference

9 February 2018

J C Alvarez

2

1 reference

9 February 2018

C Longvert

3

1 reference

9 February 2018

E Abe

4

1 reference

9 February 2018

A Beauchet

5

1 reference

9 February 2018

P Saiag

7

1 reference

9 February 2018

publication date

21 April 2015

1 reference

9 February 2018

published in

Annals of Oncology

1 reference

9 February 2018

volume

26

1 reference

9 February 2018

issue

7

1 reference

9 February 2018

page(s)

1470-1475

1 reference

9 February 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Melanoma chemotherapy leads to the selection of ABCB5-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV189

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV189

1 reference

9 February 2018

release_3jhiglh6jfgwdf6en6lh3nxcm4

Fatcat ID

0 references

1 reference

9 February 2018